INSIGHTS ON CLINICAL TRIAL DESIGN
-
![Cancer Patient At Home GettyImages-636249720]( "Advancing Ovarian Cancer Therapies: Clinical Research Trends, Challenges, And Proven Strategies")
Advancing Ovarian Cancer Therapies: Clinical Research Trends, Challenges, And Proven StrategiesOvarian cancer remains one of the deadliest gynecologic malignancies. Successful clinical trials in this space demand deep therapeutic expertise, operational agility, and global coordination.
-
![gettyimages-2200665779-170667a-scientists-tablet-talking]( "The Flexibility Of Reconsent In Clinical Trials")
The Flexibility Of Reconsent In Clinical TrialsExplore the common misconceptions surrounding reconsent, as well as the reality of its ability to be a flexible, ethics-driven communication practice grounded in respect for participant autonomy.
-
![Physical Activity]( "Digital Physical Activity Measures In Phase 3 Immunology Trials")
Digital Physical Activity Measures In Phase 3 Immunology TrialsDr. Jie Shen, Research Fellow and Director of Digital Science at AbbVie, shares lessons learned from incorporating digital measures of physical activity into Phase 3 immunology clinical trials.
-
![Cancer patient consulting with doctor-GettyImages-1217056000]( "Solutions To The Challenges Of Oncology Trials")
Solutions To The Challenges Of Oncology TrialsThis significant Phase III trial, one of the largest global studies in head and neck cancer, faced considerable challenges including enrollment delays and an intricate study design.
-
DCT Solutions That Successfully Deliver Results10/28/2025
Catch MRN COO, Todd McGrath, speaking on the impact DCT/hybrid trial design can have on overall trial success, noting that there is no "one-size-fits-all" — it takes a tailored approach to achieve maximum results.
-
What Everest Group's RTSM Recognition Means For The Industry12/5/2025
RTSM is transforming from a basic operational tool into a strategic driver of trial efficiency. Learn why industry recognition signals a new era of innovation and competitive advantage.
-
What Does 2025 Hold For Pharma?1/17/2025
Look at what’s in store for pharma and life science in 2025. While we see many recurring themes, 2025 promises to be filled with unexpected — and possibly unprecedented — developments.
-
Real-World Value Realized From DHTs In Clinical Trials10/22/2024
Explore four real-world examples of clinical trials that successfully integrated DHTs. Each case study highlights how DHTs impacted specific aspects of trial design.
-
Completed Clinical Trials Continued To Climb In 20246/19/2025
Data collected in this report reflects a shift toward sustained growth, reflecting rapid advancement in therapeutic areas such as oncology, autoimmune/inflammation, and central nervous system studies.
CLINICAL TRIAL DESIGN SOLUTIONS
-
![GettyImages- 1254443202 medical writing]( "Medical Writing Services To Support Every Submission Milestone")
Ensure accurate, compliant, and impactful documentation with Altasciences' experienced medical writers and regulatory experts.
-
![Patient- doctor- GettyImages-2155775525]( "Therapeutic Experience: Supporting Recruitment And Retention")
CSS offers customized patient recruitment and retention solutions across the globe, ensuring successful enrollment for clinical trials across various therapeutic areas.
-
![GettyImages-1938542776 doctor patient]( "Scout Clinical Trial Patient Services")
Clear the path for global clinical trial participation with 24/7 live assistance and personalized patient support.
-
![GettyImages-2160908575-patient-care-nurse]( "The Problem-Solving, Patient Advocate Team That Every Trial Needs")
Patient Kindness is a supplemental layer of premium support that offers a more seamless clinical trial experience for patients and caregivers with more complex or nuanced needs.
-
![GettyImages-1141776173 patient]( "Patient Recruitment With A Patient-Centric Approach")
At Avance Clinical, patients are our priority. We meticulously select experienced sites and clinics, alongside patient advocacy groups and communities to ensure optimal patient care and outcomes.
